Recombinant human interferon γ for injection;
Recombinant streptokinase for injection;
Pemetrexed disodium for injection.
All products have complete and systematic registration documents.
Kaimao Company will continue to develop new drugs in the field of tumor treatment, and strive to develop a number of new drugs with independent intellectual property rights and market competitiveness from the perspective of drug innovation, effectiveness and safety. At the same time, we actively organize and enhance the competitiveness of existing products in the international market, and have obtained registration certificates from many countries such as South America, Eastern Europe and Southeast Asia.